A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)
Authors: Scott Paul , Haranaka Miwa , Choi Jung Hyun , Stacey Helen , Dionne Marc , Greenberg David , Grijalva Carlos G , Orenstein Walter A , Fernsler Doreen , Gallagher Nancy , Zeng Tiantian , Li Jianing , Platt Heather L ,   for the STRIDE-6 Study Group, Chapman Timothy J , Davis Karyn , Dionne Marc , Dzongowski Peter , Girard Ginette , Tellier Guy , Tytus Richard , Jaffuel Sylvain , Nicolas Jean-Francois , Ami Eytan Ben , Bendayan Daniele , Caraco Yoseph , Chowers Michal , Darawsha Mahmud , Peer Avivit , Blasi Francesco Bruno , Castagna Antonella , Costantino Claudio , Martinelli Domenico , Haranaka Miwa , Yono Makoto , Choi Jung Hyun , Choi Won Suk , Lee Dong-Gun , Lee Jacob , Shi Hyejin , Song Joon Young , De luiz Martinez Gustavo , Echave-Sustaeta Maria-Tome Jose Maria , Aumatell Cristina Masuet , Perez Silvia Narejos , Vilella i Morato Anna , Huang Kuo-Chin , Yang Yi-Ching , Butuk David J , Cardona Jose Francisco , Daboul Nizar , Fiel Thomas , Fraser Neil J , Freeman George Hartley , Geller Steven A , Harper Charles Harold , Johnston William Henry , Lenzmeier Thomas C , Pelayo Enrique , Porterfield Laura , Rigonan Kathryn R , Rosen Jeffrey Bruce , Stacey Helen L 
Published: August 2024

Background

Pneumococcal diseases cause considerable morbidity and mortality in adults. V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) specifically designed to protect adults from pneumococcal serotypes responsible for the majority of residual pneumococcal diseases. This phase 3 study evaluated safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine–experienced adults aged ≥50 years.

Methods

A total of 717 adults were enrolled to receive a single dose of pneumococcal vaccine as follows: cohort 1 (n = 350) previously received 23-valent pneumococcal polysaccharide vaccine (PPSV23) and were randomized 2:1 to receive V116 or PCV15, respectively; cohort 2 (n = 261) previously received PCV13 and were randomized 2:1 to receive V116 or PPSV23, respectively; cohort 3 (n = 106) previously received PPSV23 + PCV13, PCV13 + PPSV23, PCV15 + PPSV23, or PCV15 and all received open-label V116. Immunogenicity was evaluated 30 days postvaccination using opsonophagocytic activity (OPA) geometric mean titers (GMTs) and immunoglobulin G (IgG) geometric mean concentrations (GMCs) for all V116 serotypes. Safety was evaluated as the proportion of participants with adverse events (AEs).

Results

V116 was immunogenic across all 3 cohorts as assessed by serotype-specific OPA GMTs and IgG GMCs postvaccination for all 21 serotypes. V116 elicited comparable immune responses to serotypes shared with PCV15 (cohort 1) or PPSV23 (cohort 2), and higher immune responses to serotypes unique to V116. The proportions of participants with solicited AEs were generally comparable across cohorts.

Conclusions

V116 is well tolerated with a safety profile comparable to currently licensed pneumococcal vaccines and generates IgG and functional immune responses to all V116 serotypes, regardless of prior pneumococcal vaccine received.

Clinical Trials Registration

NCT05420961; EudraCT 2021-006679-41.